Sanofi SA

SAN: XPAR (FRA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|@^LOCK|>b##!LOCK|xgLV^%&

Sanofi Earnings: Strong Rebound in Earnings Growth Well Underway, Led by Dupixent Sales

Sanofi reported second-quarter net sales growth of 10.1% at constant currency and business earnings per share growth of 8.3%, largely driven by Dupixent and Altuviiio. It raised full-year guidance for revenue growth to high single digits and reiterated its EPS growth target of low double digits.

Sponsor Center